Calling for a Paris Ambulance Initiative: Study on the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France shows that cost of transportation is twice cost of innovative cancer treatment. https://t.co/1GulHFFvck https:/
For evidence on risk factors and increased cost due to late intervention, see French study: https://t.co/kd2TjC2WiN - "Tobacco smoking and heavy drinking are the main risk factors for HNSCC" - "Increasing prevention and early detection strategies are like
RT @willems_sonja: At EU level cost of cancer medicines goes up while total cost of cancer care goes down. Innovative cancer medicines can…
RT @borisazais: We also need to put cost of #cancer #medicines in perspective. See head & neck cancer study: "expensive" drug represents 5%…
At EU level cost of cancer medicines goes up while total cost of cancer care goes down. Innovative cancer medicines can drive overall cost down while improving survival and QoL for patients.
We also need to put cost of #cancer #medicines in perspective. See head & neck cancer study: "expensive" drug represents 5% of total cost of cancer patient. Medical transportation represents 11%. https://t.co/baNsYvmoqy @cancereu #newdeal4meds #access
@kchalkidou @YNatsis Let's watch this space indeed! Putting costs into perspective, check out this French study on cost of head & neck cancer: cetuximab represents 5% of total cost of care, while medical transportation is at 11%... Room for efficiencie
RT @borisazais: @YNatsis "Actual expenses of targeted therapy cetuximab accounted for 28% of all chemotherapy costs, 10% of curative-intent…
RT @borisazais: @YNatsis "Actual expenses of targeted therapy cetuximab accounted for 28% of all chemotherapy costs, 10% of curative-intent…
RT @borisazais: @YNatsis "Actual expenses of targeted therapy cetuximab accounted for 28% of all chemotherapy costs, 10% of curative-intent…
@YNatsis "Actual expenses of targeted therapy cetuximab accounted for 28% of all chemotherapy costs, 10% of curative-intent treatment costs, and 5% of prevalent direct costs." So, the cost of «innovative, high priced treatment» was half that of transportat